How many Phase II readouts would it take to judge 'AI drugs still succeed 40% of the time'?
Exact binomial calculations show the uncertainty in small AI-drug phase 2 samples and the sample sizes needed for superiority or equivalence claims.
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
ORCIDGoogle ScholarLinkedInGitHub
Recent writing
Does lower DNA repair gene expression imply greater PARP inhibitor sensitivity?
Paired ZZ-FIRST expression panels distinguish coordinated repair and cell-cycle changes from functional HRR deficiency and added PARP-inhibitor benefit.
Designing the data for virtual cells: a synthetic allocation audit inspired by Biohub
Four synthetic allocations of 28,800 cells separate sampling depth, donors, condition coverage, imputation bias, and sample-preparation costs.